Multimarker model for non-invasive assessment of variceal bleeding in chronic hepatitis C cirrhotic patients

Table 2 Laboratory findings across study groups, mean ± SD

Parameter	Group I (n = 31)	Group II (n = 31)	Group III (n = 31)	P value (I vs II)1	P value (I vs III)1	P value (II vs III)1
WBCs (× 103/μL)	8.78 ± 5.75	8.55 ± 6.94	7.58 ± 2.24	0.89 (NS)	0.28 (NS)	0.46 (NS)
Hb (g/dL)	9.10 ± 1.34	9.83 ± 1.49	12.31 ± 1.86	0.04 (S)	< 0.01 (HS)	< 0.01 (HS)
PLT (× 103/μL)	97.71 ± 35.82	123.00 ± 51.61	267.97 ± 71.24	0.03 (S)	< 0.01 (HS)	< 0.01 (HS)
INR	1.47 ± 0.28	1.39 ± 0.37	1.04 ± 0.15	0.36 (NS)	< 0.01 (HS)	< 0.01 (HS)
Albumin (g/dL)	2.34 ± 0.53	2.62 ± 0.68	4.05 ± 0.58	0.08 (NS)	< 0.01 (HS)	< 0.01 (HS)
Bilirubin (mg/dL)	2.14 ± 2.00	2.44 ± 2.64	0.88 ± 1.15	0.62 (NS)	0.004 (HS)	0.004 (HS)
ALT (U/L)	46.2 ± 15.8	42.5 ± 13.9	30.1 ± 9.8	0.28 (NS)	< 0.01 (HS)	0.02 (S)
AST (U/L)	58.7 ± 18.4	55.1 ± 16.2	33.9 ± 10.7	0.37 (NS)	< 0.01 (HS)	0.01 (S)
Creatinine (mg/dL)	1.32 ± 0.41	0.94 ± 0.22	0.82 ± 0.18	< 0.01 (HS)	< 0.01 (HS)	0.03 (S)
MELD score	16.8 ± 4.5	12.1 ± 3.8		< 0.01 (HS)

¹Comparisons were performed using one-way analysis of variance followed by pairwise comparisons performed using Scheffe’s post-hoc test.

NS: Not significant; S: Significant: HS: Highly significant; WBCs: White blood cells; Hb: Hemoglobin; PLT: Platelet count; INR: International normalized ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MELD: Model for end-stage liver disease.